Elevated human dipeptidyl peptidase 4 expression reduces the susceptibility of hDPP4 transgenic mice to middle east respiratory syndrome coronavirus infection and disease

Journal of Infectious Diseases

Volumn 219, Issue 5, 2019, Pages 829-835

  Algaissi, Abdullah ^a,d   Agrawal, Anurodh S ^a   Han, Song ^b   Peng, Bi Hung ^a   Luo, Chuming ^c   Li, Fang ^c   Chan, Teh Sheng ^a   Couch, Robert B ^a   Tseng, Chien Te K ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d JAZAN UNIVERSITY   (Saudi Arabia)

Author keywords

human DPP4; medical countermeasures for MERS; MERS pathogenesis; Middle East respiratory syndrome coronavirus; transgenic mice

Indexed keywords

DIPEPTIDYL PEPTIDASE IV;

ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; HISTOPATHOLOGY; INFECTION SENSITIVITY; LD50; LUNG INFECTION; MEDICAL COUNTERMEASURE; MIDDLE EAST RESPIRATORY SYNDROME; MORBIDITY; MORTALITY RATE; MOUSE; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN EXPRESSION LEVEL; PROTEIN FUNCTION; TRANSGENIC MOUSE; VIRUS LOAD; VIRUS NEUTRALIZATION; VIRUS RESISTANCE; ANIMAL; BLOOD; CORONAVIRUS INFECTION; DISEASE MODEL; DISEASE RESISTANCE; GENE EXPRESSION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNOLOGY; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; VIROLOGY;

ANIMALS; CORONAVIRUS INFECTIONS; DIPEPTIDYL PEPTIDASE 4; DISEASE MODELS, ANIMAL; DISEASE RESISTANCE; GENE EXPRESSION; HUMANS; LETHAL DOSE 50; MICE; MICE, TRANSGENIC; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS;

EID: 85061576560     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiy574     Document Type: Conference Paper

References (21)

1. World Health Organization Regional Office for the Eastern Mediterranean. Epidemic and pandemic-prone diseases. MERS situation update, June 2018 . http://www.emro.who. int/pandemic-epidemic-diseases/mers-cov/mers-situation-update-june-2018.html. Accessed 12 July 2018.
2. Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013; 495:251-4.
3. Klemann C, Wagner L, Stephan M, von Hörsten S. Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system. Clin Exp Immunol 2016; 185:1-21.
4. Wagner L, Klemann C, Stephan M, von Hörsten S. Unravelling the immunological roles of dipeptidyl peptidase 4 (DPP4) activity and/or structure homologue (DASH) proteins. Clin Exp Immunol 2016; 184:265-83.
5. Agrawal AS, Garron T, Tao X, et al. Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. J Virol 2015; 89:3659-70.
6. Tao X, Garron T, Agrawal AS, et al. Characterization and demonstration of the value of a lethal mouse model of Middle East respiratory syndrome coronavirus infection and disease. J Virol 2016; 90:57-67.
7. Du L, Kou Z, Ma C, et al. A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERSCoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS One 2013; 8:e81587.
8. Yang Y, Du L, Liu C, et al. Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus. Proc Natl Acad Sci U S A 2014; 111:12516-21.
9. Lu G, Hu Y, Wang Q, et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 2013; 500:227-31.
10. Mamgain S, Mathur S, Kothiyal P. Imunomodulatory activity of DPP4. J Pharmacol Clin Toxicol 2013; 1:1006.
11. Lambeir AM, Durinx C, Scharpé S, De Meester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003; 40:209-94.
12. Agrawal AS, Tao X, Algaissi A, et al. Immunization with inactivated Middle East respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccin Immunother 2016; 12:2351-6.
13. Morimoto C, Schlossman SF. The structure and function of CD26 in the T-cell immune response. Immunol Rev 1998; 161:55-70.
14. Nohtomi K, Terasaki M, Kohashi K, Hiromura M, Nagashima M, Hirano T. A dipeptidyl peptidase-4 inhibitor directly suppresses inflammation and foam cell formation in monocytes/macrophages beyond incretins. Diabetologia 2014; 57(Suppl 1):S373.
15. Itou M, Kawaguchi T, Taniguchi E, Sata M. Dipeptidyl peptidase-4: a key player in chronic liver disease. World J Gastroenterol 2013; 19:2298-306.
16. Inn KS, Kim Y, Aigerim A, et al. Reduction of soluble dipeptidyl peptidase 4 levels in plasma of patients infected with Middle East respiratory syndrome coronavirus. Virology 2018; 518:324-7.
17. Hofmann H, Geier M, Marzi A, et al. Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor. Biochem Biophys Res Commun 2004; 319:1216-21.
18. Huguenel ED, Cohn D, Dockum DP, et al. Prevention of rhinovirus infection in chimpanzees by soluble intercellular adhesion molecule-1. Am J Respir Crit Care Med 1997; 155:1206-10.
19. Gardner MR, Kattenhorn LM, Kondur HR, et al. AAVexpressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature 2015; 519:87-91.
20. Saad M, Omrani AS, Baig K, et al. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. Int J Infect Dis 2014; 29:301-6.
21. Arabi YM, Balkhy HH, Hayden FG, et al. Middle East respiratory syndrome. N Engl J Med 2017; 376:584-94.